Dallas, Texas--(Newsfile Corp. - November 21, 2024) - Burcon Nutrascience Corporation (TSX: BU): Stonegate Capital Partners updates their coverage on Burcon Nutrascience Corporation (TSX: BU). In the second quarter of 2025, Burcon made significant strides in its strategic initiatives. The Company successfully ramped up commercial production of its canola protein isolate, marking a pivotal milestone in its go-to-market strategy. With over 80 prospective customers evaluating its protein products, Burcon has built a robust sales pipeline. Additionally, The Company sees a multi-billion-dollar total addressable market for its products, with specific opportunities in the soy protein isolate market (US$70-116M), pea protein market (US$215-392M), and canola protein market (US$68-113M), among others. We note that these developments position Burcon well for future growth, driven by expanding market opportunities and strategic advancements in product commercialization.
To view the full announcement, including downloadable images, bios, and more, click here.
Key Takeaways:
- Built a robust sales pipeline with over 80 prospective customers.
- Launched Puratein(R) canola protein into multi-billion-dollar egg replacement market.
- Secured a partnership with a strategic investor to acquire protein production facilities starting in 1Q25.
About Stonegate
Stonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies. Our affiliate, Stonegate Capital Markets (member FINRA) provides a full spectrum of investment banking services for public and private companies.
Contacts:
Stonegate Capital Partners
(214) 987-4121
info@stonegateinc.comSource: Stonegate, Inc.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/230946